<p>NBC Securities Inc. 在最近向证券交易委员会提交的 13F 表格中披露，在第一季度将其在赛默飞世尔（Thermo Fisher Scientific Inc.，NYSE:TMO - 免费报告）的持股比例提高了 125,200.0%。该公司在季度内购买了额外的 2,504 股后，现持有该医疗研究公司 2,506 股股票。根据其最近向证券交易委员会的提交，NBC Securities Inc. 在赛默飞世尔的持股价值为 1,246,000 美元。</p>
<ul>
<li>现金流重点：赛默飞世尔、能源转移和网易</li>
</ul>
<p>其他对冲基金和机构投资者最近也增加或减少了对该公司的持股。先锋集团（Vanguard Group Inc.）在第四季度将其在赛默飞世尔的持股提高了 0.6%。先锋集团目前持有 33,249,575 股该医疗研究公司的股票，价值 17,297,426,000 美元，在此期间又购买了 196,864 股。资本世界投资者（Capital World Investors）在第四季度将其在赛默飞世尔的持股提高了 1.1%。资本世界投资者目前持有 9,430,120 股该医疗研究公司的股票，价值 4,905,812,000 美元，在此期间又购买了 104,343 股。Geode Capital Management LLC 在第四季度将其在赛默飞世尔的持股提高了 2.6%。Geode Capital Management LLC 目前持有 7,857,385 股该医疗研究公司的股票，价值 4,075,540,000 美元，在上个季度又收购了 197,442 股。挪威银行（Norges Bank）在第四季度收购了赛默飞世尔的新股份，估计价值约为 3,149,754,000 美元。最后，北方信托公司（Northern Trust Corp）在第四季度将其在赛默飞世尔的持股提高了 13.2%。北方信托公司目前持有 3,910,015 股该医疗研究公司的股票，价值 2,034,107,000 美元，在此期间又收购了 455,004 股。机构投资者持有该公司 89.23% 的股票。</p>
<h2>内部买卖</h2>
<p>在相关消息中，执行副总裁 Gianluca Pettiti 于 4 月 28 日星期一出售了 300 股公司的股票。该股票以平均价格 429.93 美元出售，总交易额为 128,979.00 美元。出售完成后，该执行副总裁现在直接持有 23,167 股公司股票，价值 9,960,188.31 美元。这代表其持股减少了 1.28%。该出售在向证券交易委员会的提交中披露，相关信息可通过此链接获取。此外，高级副总裁 Michael A. Boxer 于 3 月 10 日星期一出售了 3,775 股赛默飞世尔的股票。该股票以平均价格 532.52 美元出售，总价值为 2,010,263.00 美元。交易完成后，该高级副总裁现在持有 10,816 股公司股票，价值约 5,759,736.32 美元。这代表其持股减少了 25.87%。该出售的披露信息可在此处找到。公司内部人士持有 0.33% 的股票。</p>
<h2>赛默飞世尔的价格表现</h2>
<ul>
<li>安捷伦科技因 “永恒化学品” 打击而蓬勃发展</li>
</ul>
<p>TMO 的股票在周二开盘价为 396.08 美元。该公司的市值为 1495.2 亿美元，市盈率为 23.96，市盈增长比率为 2.99，贝塔值为 0.82。公司的债务与股本比率为 0.59，流动比率为 1.66，速动比率为 1.29。公司的 50 日移动平均线为 428.50 美元，200 日移动平均线为 498.72 美元。赛默飞世尔的 52 周低点为 390.50 美元，52 周高点为 627.88 美元。</p>
<p>赛默飞世尔（NYSE:TMO - 获取免费报告）最近于 4 月 23 日星期三发布了季度财报。该医疗研究公司报告的季度每股收益为 5.15 美元，超出分析师一致预期的 5.10 美元，超出幅度为 0.05 美元。该公司季度收入为 103.6 亿美元，而分析师预期为 102.3 亿美元。赛默飞世尔的净利润率为 14.78%，股本回报率为 17.51%。与去年同期相比，赛默飞世尔的季度收入增长了 0.2%。去年同期，该公司每股收益为 5.11 美元。股票分析师预测赛默飞世尔将在当前年度发布 23.28 美元的每股收益。</p>
<h2>赛默飞世尔的股息公告</h2>
<ul>
<li>S&amp;P 500 中增长最快的 4 个股息：买入、卖出还是持有？</li>
</ul>
<p>该公司还最近宣布了一项季度股息，将于 7 月 15 日星期二支付。6 月 13 日星期五的股东将获得每股 0.43 美元的股息。这代表年化股息为 1.72 美元，股息收益率为 0.43%。除息日期为 6 月 13 日星期五。赛默飞世尔的股息支付比率（DPR）目前为 10.09%。</p>
<h2>分析师升级和降级</h2>
<p>几位研究分析师最近对 TMO 股票发表了看法。花旗集团在 3 月 4 日的研究报告中将赛默飞世尔的目标价从 650.00 美元下调至 570.00 美元，并对该公司给予了 “中性” 评级。加拿大皇家银行在 4 月 24 日的研究报告中将赛默飞世尔的目标价从 651.00 美元下调至 637.00 美元，并对该公司给予了 “跑赢大盘” 评级。富国银行在 4 月 24 日的报告中将赛默飞世尔的目标价从 580.00 美元下调至 570.00 美元，并对该股票给予了 “增持” 评级。罗伯特·W·贝尔德在 4 月 24 日的研究报告中将赛默飞世尔的目标价从 603.00 美元下调至 573.00 美元，并对该公司给予了 “跑赢大盘” 评级。最后，斯蒂费尔·尼古拉斯在 4 月 24 日的研究报告中将赛默飞世尔的目标价从 665.00 美元下调至 620.00 美元，并对该股票给予了 “买入” 评级。四位投资分析师对该股票给予了持有评级，十八位分析师对该公司的股票给予了买入评级。根据 MarketBeat.com 的数据，赛默飞世尔目前的共识评级为 “适度买入”，共识目标价为 607.43 美元。</p>
<p><strong>查看我们对 TMO 的最新分析</strong></p>
<h2>赛默飞世尔公司简介</h2>
<p>（免费报告）</p>
<p>赛默飞世尔科技公司在北美、欧洲、亚太地区及国际市场提供生命科学解决方案、分析仪器、专业诊断、实验室产品和生物制药服务。公司的生命科学解决方案部门为生物和医学研究、药物和疫苗的发现与生产，以及感染和疾病的诊断提供试剂、仪器和耗材；解决方案包括生物科学、遗传科学和生物生产，服务于制药、生物技术、农业、临床、医疗保健、学术和政府市场。</p>
<h2>另请参见</h2>
<ul>
<li>我们更看好的五只股票比赛默飞世尔更具吸引力</li>
<li>英国市场假期有哪些？如何投资和交易</li>
<li>Ulta 的美丽第一季度财报预示着更多收益</li>
<li>如何投资最佳的加拿大股票</li>
<li>国防鹰派正在购买的前三只 ETF</li>
<li>如何捕捉股息增加的好处</li>
<li>Zscaler 将很快达到 360 美元：这是如何和为什么</li>
</ul>
<p><strong>想知道其他对 TMO 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取赛默飞世尔科技公司（NYSE:TMO - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRNTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRNTw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在赛默飞世尔吗？</h2>
<p>在考虑赛默飞世尔之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前...而赛默飞世尔并不在名单上。</p>
<p>虽然赛默飞世尔目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

赛默飞世尔

<p>NBC Securities Inc. 在第一季度大幅增加了对赛默飞世尔的持股，增幅达到 125,200%，额外购入了 2,504 股，使其总持股量达到 2,506 股，价值 125 万美元。其他机构投资者，包括先锋集团和资本世界投资者，也提高了他们的持股比例。赛默飞世尔的股票开盘价为 396.08 美元，市值为 1,495.2 亿美元。该公司报告第一季度每股收益为 5.15 美元，超出预期，并宣布每股季度股息为 0.43 美元，将于 7 月 15 日支付</p>

<p>NBC Securities Inc. raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 125,200.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,506 shares of the medical research company's stock after buying an additional 2,504 shares during the quarter. NBC Securities Inc.'s holdings in Thermo Fisher Scientific were worth $1,246,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>NBC Securities Inc. 在最近向证券交易委员会提交的 13F 表格中披露，在第一季度将其在赛默飞世尔（Thermo Fisher Scientific Inc.，NYSE:TMO - 免费报告）的持股比例提高了 125,200.0%。该公司在季度内购买了额外的 2,504 股后，现持有该医疗研究公司 2,506 股股票。根据其最近向证券交易委员会的提交，NBC Securities Inc. 在赛默飞世尔的持股价值为 1,246,000 美元。</p>
</div><ul>
<li>Cash Flow Focus: Thermo Fisher, Energy Transfer, and NetEase</li>
</ul>
<div class="lb-trans"><ul>
<li>现金流重点：赛默飞世尔、能源转移和网易</li>
</ul>
</div><p>Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Thermo Fisher Scientific by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 33,249,575 shares of the medical research company's stock worth $17,297,426,000 after purchasing an additional 196,864 shares during the period. Capital World Investors raised its stake in Thermo Fisher Scientific by 1.1% during the 4th quarter. Capital World Investors now owns 9,430,120 shares of the medical research company's stock worth $4,905,812,000 after buying an additional 104,343 shares during the period. Geode Capital Management LLC increased its holdings in shares of Thermo Fisher Scientific by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 7,857,385 shares of the medical research company's stock worth $4,075,540,000 after acquiring an additional 197,442 shares in the last quarter. Norges Bank acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $3,149,754,000. Finally, Northern Trust Corp raised its holdings in shares of Thermo Fisher Scientific by 13.2% during the fourth quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company's stock worth $2,034,107,000 after acquiring an additional 455,004 shares during the period. Institutional investors own 89.23% of the company's stock.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者最近也增加或减少了对该公司的持股。先锋集团（Vanguard Group Inc.）在第四季度将其在赛默飞世尔的持股提高了 0.6%。先锋集团目前持有 33,249,575 股该医疗研究公司的股票，价值 17,297,426,000 美元，在此期间又购买了 196,864 股。资本世界投资者（Capital World Investors）在第四季度将其在赛默飞世尔的持股提高了 1.1%。资本世界投资者目前持有 9,430,120 股该医疗研究公司的股票，价值 4,905,812,000 美元，在此期间又购买了 104,343 股。Geode Capital Management LLC 在第四季度将其在赛默飞世尔的持股提高了 2.6%。Geode Capital Management LLC 目前持有 7,857,385 股该医疗研究公司的股票，价值 4,075,540,000 美元，在上个季度又收购了 197,442 股。挪威银行（Norges Bank）在第四季度收购了赛默飞世尔的新股份，估计价值约为 3,149,754,000 美元。最后，北方信托公司（Northern Trust Corp）在第四季度将其在赛默飞世尔的持股提高了 13.2%。北方信托公司目前持有 3,910,015 股该医疗研究公司的股票，价值 2,034,107,000 美元，在此期间又收购了 455,004 股。机构投资者持有该公司 89.23% 的股票。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In related news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares in the company, valued at $9,960,188.31. This represents a 1.28% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this link. Also, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the transaction, the senior vice president now owns 10,816 shares in the company, valued at approximately $5,759,736.32. This represents a 25.87% decrease in their position. The disclosure for this sale can be found here. 0.33% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，执行副总裁 Gianluca Pettiti 于 4 月 28 日星期一出售了 300 股公司的股票。该股票以平均价格 429.93 美元出售，总交易额为 128,979.00 美元。出售完成后，该执行副总裁现在直接持有 23,167 股公司股票，价值 9,960,188.31 美元。这代表其持股减少了 1.28%。该出售在向证券交易委员会的提交中披露，相关信息可通过此链接获取。此外，高级副总裁 Michael A. Boxer 于 3 月 10 日星期一出售了 3,775 股赛默飞世尔的股票。该股票以平均价格 532.52 美元出售，总价值为 2,010,263.00 美元。交易完成后，该高级副总裁现在持有 10,816 股公司股票，价值约 5,759,736.32 美元。这代表其持股减少了 25.87%。该出售的披露信息可在此处找到。公司内部人士持有 0.33% 的股票。</p>
</div><h2>Thermo Fisher Scientific Price Performance</h2>
<div class="lb-trans"><h2>赛默飞世尔的价格表现</h2>
</div><ul>
<li>Agilent Technologies Thrives From the Forever Chemicals Crackdown</li>
</ul>
<div class="lb-trans"><ul>
<li>安捷伦科技因 “永恒化学品” 打击而蓬勃发展</li>
</ul>
</div><p>Shares of TMO opened at $396.08 on Tuesday. The firm has a market capitalization of $149.52 billion, a PE ratio of 23.96, a PEG ratio of 2.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The company's 50-day moving average is $428.50 and its 200-day moving average is $498.72. Thermo Fisher Scientific Inc. has a fifty-two week low of $390.50 and a fifty-two week high of $627.88.</p>
<div class="lb-trans"><p>TMO 的股票在周二开盘价为 396.08 美元。该公司的市值为 1495.2 亿美元，市盈率为 23.96，市盈增长比率为 2.99，贝塔值为 0.82。公司的债务与股本比率为 0.59，流动比率为 1.66，速动比率为 1.29。公司的 50 日移动平均线为 428.50 美元，200 日移动平均线为 498.72 美元。赛默飞世尔的 52 周低点为 390.50 美元，52 周高点为 627.88 美元。</p>
</div><p>Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. The business had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Thermo Fisher Scientific's revenue for the quarter was up .2% compared to the same quarter last year. During the same period last year, the firm earned $5.11 earnings per share. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.</p>
<div class="lb-trans"><p>赛默飞世尔（NYSE:TMO - 获取免费报告）最近于 4 月 23 日星期三发布了季度财报。该医疗研究公司报告的季度每股收益为 5.15 美元，超出分析师一致预期的 5.10 美元，超出幅度为 0.05 美元。该公司季度收入为 103.6 亿美元，而分析师预期为 102.3 亿美元。赛默飞世尔的净利润率为 14.78%，股本回报率为 17.51%。与去年同期相比，赛默飞世尔的季度收入增长了 0.2%。去年同期，该公司每股收益为 5.11 美元。股票分析师预测赛默飞世尔将在当前年度发布 23.28 美元的每股收益。</p>
</div><h2>Thermo Fisher Scientific Dividend Announcement</h2>
<div class="lb-trans"><h2>赛默飞世尔的股息公告</h2>
</div><ul>
<li>Top 4 Fastest Growing S&amp;P 500 Dividends: Buy, Sell, or Hold?</li>
</ul>
<div class="lb-trans"><ul>
<li>S&amp;P 500 中增长最快的 4 个股息：买入、卖出还是持有？</li>
</ul>
</div><p>The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.43%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.09%.</p>
<div class="lb-trans"><p>该公司还最近宣布了一项季度股息，将于 7 月 15 日星期二支付。6 月 13 日星期五的股东将获得每股 0.43 美元的股息。这代表年化股息为 1.72 美元，股息收益率为 0.43%。除息日期为 6 月 13 日星期五。赛默飞世尔的股息支付比率（DPR）目前为 10.09%。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>Several research analysts have recently weighed in on TMO shares. Citigroup reduced their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a &#34;neutral&#34; rating for the company in a research report on Tuesday, March 4th. Royal Bank of Canada reduced their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an &#34;outperform&#34; rating for the company in a research report on Thursday, April 24th. Wells Fargo &amp; Company lowered their price objective on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an &#34;overweight&#34; rating on the stock in a report on Thursday, April 24th. Robert W. Baird decreased their target price on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an &#34;outperform&#34; rating for the company in a research report on Thursday, April 24th. Finally, Stifel Nicolaus cut their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a &#34;buy&#34; rating on the stock in a research report on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $607.43.</p>
<div class="lb-trans"><p>几位研究分析师最近对 TMO 股票发表了看法。花旗集团在 3 月 4 日的研究报告中将赛默飞世尔的目标价从 650.00 美元下调至 570.00 美元，并对该公司给予了 “中性” 评级。加拿大皇家银行在 4 月 24 日的研究报告中将赛默飞世尔的目标价从 651.00 美元下调至 637.00 美元，并对该公司给予了 “跑赢大盘” 评级。富国银行在 4 月 24 日的报告中将赛默飞世尔的目标价从 580.00 美元下调至 570.00 美元，并对该股票给予了 “增持” 评级。罗伯特·W·贝尔德在 4 月 24 日的研究报告中将赛默飞世尔的目标价从 603.00 美元下调至 573.00 美元，并对该公司给予了 “跑赢大盘” 评级。最后，斯蒂费尔·尼古拉斯在 4 月 24 日的研究报告中将赛默飞世尔的目标价从 665.00 美元下调至 620.00 美元，并对该股票给予了 “买入” 评级。四位投资分析师对该股票给予了持有评级，十八位分析师对该公司的股票给予了买入评级。根据 MarketBeat.com 的数据，赛默飞世尔目前的共识评级为 “适度买入”，共识目标价为 607.43 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on TMO</strong></p>
<div class="lb-trans"><p><strong>查看我们对 TMO 的最新分析</strong></p>
</div><h2>Thermo Fisher Scientific Profile</h2>
<div class="lb-trans"><h2>赛默飞世尔公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.</p>
<div class="lb-trans"><p>赛默飞世尔科技公司在北美、欧洲、亚太地区及国际市场提供生命科学解决方案、分析仪器、专业诊断、实验室产品和生物制药服务。公司的生命科学解决方案部门为生物和医学研究、药物和疫苗的发现与生产，以及感染和疾病的诊断提供试剂、仪器和耗材；解决方案包括生物科学、遗传科学和生物生产，服务于制药、生物技术、农业、临床、医疗保健、学术和政府市场。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参见</h2>
</div><ul>
<li>Five stocks we like better than Thermo Fisher Scientific</li>
<li>What Are the U.K. Market Holidays? How to Invest and Trade</li>
<li>Ulta’s Beautiful Q1 Earnings Report Points to More Gains Ahead</li>
<li>How to Invest in the Best Canadian Stocks</li>
<li>Top 3 ETFs Defense Hawks Are Buying</li>
<li>How to Capture the Benefits of Dividend Increases</li>
<li>Zscaler Will Hit $360 Soon: Here’s the How and Why</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比赛默飞世尔更具吸引力</li>
<li>英国市场假期有哪些？如何投资和交易</li>
<li>Ulta 的美丽第一季度财报预示着更多收益</li>
<li>如何投资最佳的加拿大股票</li>
<li>国防鹰派正在购买的前三只 ETF</li>
<li>如何捕捉股息增加的好处</li>
<li>Zscaler 将很快达到 360 美元：这是如何和为什么</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TMO?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 TMO 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取赛默飞世尔科技公司（NYSE:TMO - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRNTw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=TMO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Thermo Fisher Scientific Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在赛默飞世尔吗？</h2>
</div><p>Before you consider Thermo Fisher Scientific, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑赛默飞世尔之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前...而赛默飞世尔并不在名单上。</p>
</div><p>While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然赛默飞世尔目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

NBC 证券公司收购了赛默飞世尔公司（NYSE:TMO）2,504 股股票